US20190248830A1 - Proliposomal testosterone undecanoate formulations - Google Patents

Proliposomal testosterone undecanoate formulations Download PDF

Info

Publication number
US20190248830A1
US20190248830A1 US16/068,190 US201716068190A US2019248830A1 US 20190248830 A1 US20190248830 A1 US 20190248830A1 US 201716068190 A US201716068190 A US 201716068190A US 2019248830 A1 US2019248830 A1 US 2019248830A1
Authority
US
United States
Prior art keywords
tsx
dosage form
oral dosage
ratio
dspc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/068,190
Other languages
English (en)
Inventor
Guru V. Betageri
Ramachandran Thirucote
Veeran Gowda KADAJI
Natarajan VENKATESAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Western University of Health Sciences
TesorRx Pharma LLC
Original Assignee
Western University of Health Sciences
TesorRx Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western University of Health Sciences, TesorRx Pharma LLC filed Critical Western University of Health Sciences
Priority to US16/068,190 priority Critical patent/US20190248830A1/en
Assigned to WESTERN UNIVERSITY OF HEALTH SCIENCES reassignment WESTERN UNIVERSITY OF HEALTH SCIENCES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BETAGERI, GURU V.
Assigned to TESORX PHARMA, LLC reassignment TESORX PHARMA, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: THIRUCOTE, RAMACHANDRAN, KADAJJI, VEERAN GOWDA, VENKATESAN, Natarajan
Assigned to TESORX PHARMA, LLC reassignment TESORX PHARMA, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: THIRUCOTE, RAMACHANDRAN, KADAJJI, VEERAN GOWDA, VENKATESAN, Natarajan
Assigned to WESTERN UNIVERSITY OF HEALTH SCIENCES reassignment WESTERN UNIVERSITY OF HEALTH SCIENCES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BETAGERI, GURU V.
Publication of US20190248830A1 publication Critical patent/US20190248830A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Definitions

  • the invention relates to proliposomal powder dispersion formulations and oral dosage forms for the improved delivery of testosterone undeconoate.
  • TRT testosterone replacement therapy
  • TU testosterone undecanoate
  • proliposomal formulation are dry powders, they, unlike liquid suspensions of liposomes, can be incorporated into oral dosage forms which are coated with a delayed release coating (e.g., an enteric coating) that will protect the formulation until it reaches the less hostile, aqueous environment of the small intestine, where hydration of the prolipomal powder dispersion can occur to cause the formation of liposomes that deliver TU to the intestinal epithelium.
  • a delayed release coating e.g., an enteric coating
  • the invention relates to compositions of proliposomal formulations that contain a proliposomal powder dispersion of testosterone undecanoate (TU) and distearoyl phosphatidylcholine (DSPC). These powder dispersions can be incorporated into oral dosage forms which are used to deliver an effective dose of TU with minimal intererence from food effects, and therefore, are useful for treating diseases, disorders, or conditions characterized by testosterone deficiency.
  • TU testosterone undecanoate
  • DSPC distearoyl phosphatidylcholine
  • the proliposomal powder dispersions of the invention are characterized by containing TU and DSPC in specified weight/weight (w/w) ratios that correlate with significant improvements in TU release and bioavailability. More specifically, the (TU) and (DSPC) are present in the dispersion in a w/w ratio of (a):(b), respectively, that ranges from (1.0:1.0) to (1.0:4.0).
  • the proliposomal powder dispersion of an oral dosage form of the invention contains a TU dosage amount equivalent to a therapeutic dose (human equivalent dose) of testosterone 60 to 729 mg per day, and is in the form of a capsule with a delayed release coating.
  • Coated oral dosage forms of the invention can be used to bring the plasma concentration of testosterone of an individual suffering from low endogenous testosterone levels to a normal physiological concentration.
  • FIG. 1 shows dissolution data for the following TU formulations: TU1-044 (non-coated, non-capsulated, unformulated TU); TU1-076 (coated, capsulated, unformulated TU); TU1-040 (coated, capsulated TU:DSPC:Chol (1:0.9:0.1)); TU1-061c (coated, capsulated TU:DSPC:Chol:TPGS (1:0.9:0.1:0.05)); TU1-061a (coated, capsulated TU:DSPC:Chol:TPGS (1:0.9:0.1:0.2)); TU2-027 (coated, capsulated TU:DSPC (1:1)); TU2-028 (coated, capsulated TU:DSPC (1:2)); TU2-029 (coated, capsulated TU:DSPC (1:4)); and TU2-030 (coated, capsulated TU:90 HH (1:1)).
  • FIG. 2A shows plasma ‘T’ levels over a 24 hour time period in female beagle dogs following oral administration of testosterone (T) formulation TSX-002 coated, capsulated T:DSPC:Chol (1:0.9:0.1)) at days 1 and 7 of being places under fasted and fed conditions.
  • T dosage 7.5 mg/kg/OD.
  • TSX-002 Solid black line and circle time point markers
  • Day 7 fasted TSX-002 Hashed black line and circle time point markers
  • Day 1 fed, TSX-002 Dotted black line and triangle time point markers
  • Day 1 fasted unformulated T Solid grey line and triangle marking time points
  • Day 7 fasted unformulated T Solid light grey line and square time point markers
  • Day 1 fed unformulated T Solid black line and square time point markers
  • Day 7 fed unformulated T Solid grey line and crosshair time point markers.
  • FIG. 2B shows plasma ‘T’ levels over a 24 hour time period in female beagle dogs following oral administration of testosterone (T) formulation TSX-007 coated, capsulated T:DSPC:Chol:TPGS (1:0.9:0.1:0.2)) at days 1 and 7 of being places under fasted and fed conditions.
  • T dosage 7.5 mg/kg/OD.
  • TSX-007 Solid black line and circle time point markers
  • Day 7 fasted TSX-007 Hashed black line and circle time point markers
  • Day 1 fed TSX-007—Dotted black line and triangle time point markers
  • Day 1 fasted unformulated T Solid grey line and triangle marking time points
  • Day 7 fasted unformulated T Solid light grey line and square time point markers
  • Day 1 fed unformulated T Solid black line and square time point markers
  • Day 7 fed unformulated T Solid grey line and crosshair time point markers.
  • FIG. 2C shows plasma ‘T’ levels over a 24 hour time period in female beagle dogs following oral administration of testosterone undecanoate (TU) formulation TSX-009 coated, capsulated (TU:DSPC:Chol:TPGS:MC (1.0:0.9:0.1:0.2:0.6)) at days 1 and 7 of being places under fasted and fed conditions.
  • TU dosage 7.5 mg/kg/OD.
  • TSX-009 Solid black line and circle timepoint markers
  • Day 7 fasted TSX-009 Hashed black line and circle timepoint markers
  • Day 1 fed, TSX-009 Dotted black line and triangle timepoint markers
  • Day 1 fasted unformulated T Solid grey line and triangle marking timepoints
  • Day 7 fasted unformulated T Solid light grey line and square timepoint markers
  • Day 1 fed unformulated T Solid black line and square timepoint markers
  • Day 7 fed unformulated T Solid grey line and crosshair timepoint markers.
  • FIG. 5A shows plasma ‘T’ levels over a 24 hour time period following TU treatment with formulations TSX-010 (TU:Lipid, 1:1), TSX-011 (TU:Lipid, 1:2), and TSX-012 (TU:Lipid, 1:4) in female beagle dogs following oral administration of 3.75 mg/kg/QD under fasted conditions.
  • FIG. 6A shows plasma ‘T’ levels over a 24 hour time period following TU treatment with formulations TSX-010 (TU:Lipid, 1:1), TSX-011 (TU:Lipid, 1:2), and TSX-012 (TU:Lipid, 1:4) in female beagle dogs following oral administration of 7.5 mg/kg/QD under fasted conditions.
  • FIG. 7A shows plasma ‘T’ levels over a 24 hour time period TU treatment with formulations TSX-010 (TU:Lipid, 1:1), TSX-011 (TU:Lipid, 1:2), and TSX-012 (TU:Lipid, 1:4) in female beagle dogs following oral administration of 1.875 mg/kg/QD under fed conditions.
  • FIG. 8A shows plasma ‘T’ levels over a 24 hour time period following TU treatment with formulations TSX-010 (TU:Lipid, 1:1), TSX-011 (TU:Lipid, 1:2), and TSX-012 (TU:Lipid, 1:4) in female beagle dogs following oral administration of 3.75 mg/kg/QD under fed conditions.
  • FIG. 9A shows plasma ‘T’ levels over a 24 hour time period following TU treatment with formulations TSX-010 (TU:Lipid, 1:1), TSX-011 (TU:Lipid, 1:2), and TSX-012 (TU:Lipid, 1:4) in female beagle dogs following oral administration of 7.5 mg/kg/QD under fed conditions.
  • the invention relates to compositions of proliposomal formulations of testosterone undecanoate (TU), and oral dosage forms that contain proliposomal formulations of TU, which are used to deliver an effective dose of TU with minimal food effects.
  • the invention also relates to methods for preparing proliposomal formulations and dosage forms of the invention, and methods and uses of the formulations and dosage forms of the invention for treating diseases, disorders, or conditions characterized by testosterone deficiency.
  • a proliposomal formulation of the invention at least contains a proliposomal powder dispersion of TU and distearoyl phosphatidylcholine (DSPC), which are combined in a specified weight/weight (w/w) ratio that correlates with significant improvements in TU release and bioavailability. More specifically, the (TU) and (DSPC) are present in the dispersion in a w/w ratio of (a):(b), respectively, that ranges from (1.0:1.0) to (1.0:4.0).
  • TU tristearoyl phosphatidylcholine
  • (TU) and (DSPC) are present in a proliposomal powder dispersion of the invention in a w/w ratio of (a):(b) that is (1.0:1.10), (1.0:1.20), (1.0:1.30), (1.0:1.40), (1.0:1.50), (1.0:1.60), (1.0:1.70), (1.0:1.80), (1.0:1.90), (1.0:2.00), (1.0:2.10), (1.0:2.20), (1.0:2.30), (1.0:2.40), (1.0:2.50), (1.0:2.60), (1.0:2.70), (1.0:2.80), (1.0:2.90), (1.0:3.00), (1.0:3.10), (1.0:3.20), (1.0:3.30), (1.0:3.40), (1.0:3.50), (1.0:3.60), (1.0:3.70), (1.0:3.80), (1.0:3.90), (1.0:4.0), or any w/w ratio therein.
  • a preferred proliposomal powder dispersion of the invention contains TU and DS
  • a proliposomal powder dispersion of the invention can also consist essentially of (TU) and (DSPC) in a w/w ratio of (a):(b) that is (1.0:1.10), (1.0:1.20), (1.0:1.30), (1.0:1.40), (1.0:1.50), (1.0:1.60), (1.0:1.70), (1.0:1.80), (1.0:1.90), (1.0:2.00), (1.0:2.10), (1.0:2.20), (1.0:2.30), (1.0:2.40), (1.0:2.50), (1.0:2.60), (1.0:2.70), (1.0:2.80), (1.0:2.90), (1.0:3.00), (1.0:3.10), (1.0:3.20), (1.0:3.30), (1.0:3.40), (1.0:3.50), (1.0:3.60), (1.0:3.70), (1.0:3.80), (1.0:3.90), (1.0:4.0), or any w/w ratio therein.
  • a preferred proliposomal powder dispersion of the invention consists essentially
  • a proliposomal powder dispersion of the invention can also consist of (TU) and (DSPC) in a w/w ratio of (a):(b) that is (1.0:1.10), (1.0:1.20), (1.0:1.30), (1.0:1.40), (1.0:1.50), (1.0:1.60), (1.0:1.70), (1.0:1.80), (1.0:1.90), (1.0:2.00), (1.0:2.10), (1.0:2.20), (1.0:2.30), (1.0:2.40), (1.0:2.50), (1.0:2.60), (1.0:2.70), (1.0:2.80), (1.0:2.90), (1.0:3.00), (1.0:3.10), (1.0:3.20), (1.0:3.30), (1.0:3.40), (1.0:3.50), (1.0:3.60), (1.0:3.70), (1.0:3.80), (1.0:3.90), (1.0:4.0), or any w/w ratio therein.
  • a preferred proliposomal powder dispersion of the invention consists of TU and
  • a proliposomal powder dispersion of the invention can be prepared by dissolving TU in a solvent.
  • Heat (e.g., 45-55° C.) can optionally be applied during dissolution.
  • the solvent is any solvent in which TU dissolves, but is preferably a water-miscible solvent such as ethanol; however, the solvent should generally not contain 10% or more of water (vol/vol).
  • Other exemplary solvents include methanol, chloroform, dichloromethane, acetone, isopropyl alcohol, and diethyl ether.
  • the solvent is removed by any suitable technique, such as, by evaporation, by placing the solution under vacuum, by spray-drying, or by use of a drying gas, and the like.
  • the solvent removal process continues until a dry mass of the TU and DSPC dispersion forms.
  • the average particle size of resulting powder dispersion can be reduced by grinding, passing the powder through screens, or by any other suitable technique.
  • the particles within a proliposomal powder dispersion can have powder size ranging from about 10 to 200 mesh, 20 to 120 mesh or 40 to 60 or 60 to 80 mesh.
  • the proliposomal powder dispersion can undergo further drying to remove or reduce the amount of any residual solvent still present in the powder. Such a further drying step is performed by using one or more of the drying techniques discussed above or by other suitable drying technique.
  • An oral dosage form of the invention contains a proliposomal powder of the invention, which contains a therapeutic dose of TU 95 to 1152 mg per day.
  • Such oral dosage forms can also contain one or more pharmaceutically acceptable excipients in addition to a proliposomal powder.
  • an excipient or excipients, in an oral dosage form of the invention are added externally to the proliposomal powder dispersion.
  • excipients are admixed with a dry proliposomal powder dispersion containing TU and DSPC.
  • an oral dosage form of the invention can contain a proliposomal powder dispersion of the invention admixed with microcrystalline cellulose, or sodium starch glycolate, or both.
  • other exemplary pharmaceutically acceptable excipients for oral dosage forms of the invention include: (a) fillers or extenders, such as starches, lactose (e.g., lactose monohydrate), sucrose, glucose, mannitol, and silicic acid; (b) binders, such as cellulose derivatives like microcrystalline cellulose (e.g., the various Avicel® PH products like Avicel® PH-101 and PH-102, and Prosolv® products like Prosolv® SMCC 90 and 90 HD), starch, aliginates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia; (c) humectants, such as glycerol; (d) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, sodium starch glycolate (e.g., Explotab® disintegrant), alginic acid, cros
  • fillers or extenders such as starches, lactose (e
  • the w/w ratio of an excipient to the proliposomal powder dispersion component of an oral dosage form of the invention may be, but is not necessarily, critical to its desired TU release characteristics. More specifically, pharmacokinetic (PK) parameters, such as blood plasma testosterone concentration, area under the curve (AUC), maximum plasma concentration (Cmax), and amount of time taken to reach the maximum concentration (Tmax) values may correlate to certain w/w ratios of proliposomal powder dispersion to excipients.
  • PK pharmacokinetic
  • the w/w ratio of a proliposomal powder dispersion to microcrystalline cellulose in an oral dosage form of the invention can be (1.0:1.0), (1.0:1.01), (1.0:1.02), (1.0:1.03), (1.0:1.04), (1.0:1.05), (1.0:1.06), (1.0:1.07), (1.0:1.08), (1.0:1.09), or (1.0:1.10), (1.0:1.5), (1.0:2.0), (1.0:1.3.0), (1.0:4.0), or any ratio therein.
  • a preferred oral dosage form contains a proliposomal powder dispersion of TU and DSPC in a w/w ratio, (a):(b), of (1.0:2.0) in combination with microcrystalline cellulose in a w/w ratio of (1.0:1.06).
  • the w/w ratio of a proliposomal powder dispersion to sodium starch glycolate (SSG) in an oral dosage form of the invention can be (1.0:0.050), (1.0:0.051), (1.0:0.052), (1.0:0.053), (1.0:0.054), (1.0:0.055), (1.0:0.056), (1.0:0.057), (1.0:0.058), (1.0:0.059), (1.0:0.060), (1.0:0.061), (1.0:0.062), (1.0:0.063), (1.0:0.064), (1.0:0.065), (1.0:0.066), (1.0:0.067), (1.0:0.068), (1.0:0.069), (1.0:0.070), (1.0:0.071), (1.0:0.072), (1.0:0.073), (1.0:0.074), (1.0:0.075), (1.0:0.076), (1.0:0.077), (1.0:0.050), (1.0:0.051), (1.0:0.052), (1.0:0.053), (1.0:0.054), (1.0:0.055), (1.0:0.056), (1.0:0.057),
  • a preferred oral dosage form contains a proliposomal powder dispersion of TU and DSPC in a w/w ratio, (a):(b), of (1.0:2.0) in combination with SSG in a w/w ratio of (1.0:0.064).
  • Another preferred oral dosage form of the invention contains a proliposomal powder dispersion of TU and DSPC in a w/w ratio, (a):(b), of (1.0:2.0) in combination with microcrystalline cellulose and SSG in w/w ratios of dispersion:microcrystalline cellulose:SSG of 1.0:1.06:0.064.
  • Yet another preferred oral dosage form of the invention consists, or optionally, consists essentially of, a proliposomal powder dispersion of TU and DSPC in a w/w ratio, (a):(b), of (1.0:2.0) in combination with microcrystalline cellulose and SSG in w/w ratios of dispersion:microcrystalline cellulose:SSG of 1.0:1.06:0.064.
  • An oral dosage form of the invention contains a therapeutic dose, or partial therapeutic dose, of TU, which for an adult human, is from 95.9 to 1,580 mg/day, the equivalent of 60.75 to 1000 mg of testosterone per day.
  • a preferred oral dosage form of the invention can contain about (i.e., within 10% of) 95 mg, 120 mg, 190 mg, 380 mg TU, or 760 mg of TU.
  • An oral dosage form of the invention is typically a capsule. More specifically, a capsule dosage form of the invention can be soft or hard capsule, and is generally made from animal-derived gelatin or plant-derived hydroxypropyl methylcellulose (HPMC).
  • HPMC hydroxypropyl methylcellulose
  • the size of a capsule for an oral dosage form of the invention can be any size that is sufficient to contain its proliposomal powder dispersion and excipient components.
  • the capsule can be a size 5, 4, 3, 2, 1, 0, 0E, 00, 000, 13, 12, 12el, 11, 10, 7, or Su07. Capsules are filled using any suitable techniques.
  • Filled capsules can be coated with a delayed release coating, also referred to as an enteric coating.
  • a delayed release coating protects an oral dosage form of the invention from the harsh, acidic environment of the stomach, so that the release of the proliposomal powder dispersion can be delayed until the dosage form reaches the small intestine.
  • the proliposomal powder dispersion Upon contact with small intestinal fluid, the proliposomal powder dispersion is hydrated, leading to the formation of liposomes and uptake of the TU through the small intestine epithelium or lymphatic system, or both.
  • Any coatings of oral dosage forms of the invention are applied to a sufficient thickness such that the entire coating does not dissolve in the gastrointestinal fluids at pH below about 5.
  • a delayed release coating typically includes a polymer, such as an aqueous dispersion of anionic polymers with methacrylic acid as a functional group like the product sold as Eudragit® L30D-55 (Evonik Industries).
  • a delayed release coating can also optionally include a plasticizer, such as triethyl citrate, an anti-tacking agent, such as talc, and a diluent, such as water.
  • a coating composition used to coat and oral dosage form of the invention can contain about 42% (wt %) of an aqueous dispersion of anionic polymers with methacrylic acid as a functional group; about 1.25 wt % of a plasticizer; about 6.25 wt % of an anti-tacking agent; and about 51 wt % of a diluent.
  • a coating composition can be applied to capsules of the invention by using a Procept® coating machine and Caleva® mini coater air suspension coating machine to coat the capsules until they experience a 10% to 18% weight gain.
  • the proliposomal powder dispersions and oral dosage forms of the invention can be used for testosterone replacement therapy (TRT).
  • TRT testosterone replacement therapy
  • Low endogenous testosterone is another term used to describe a sub-physiological testosterone level, which is generally considered to be plasma testosterone concentration of less than 300 ng/dL.
  • Low endogenous testosterone levels can result from consequences of injury, infection, loss of testicles, chemotherapy, radiation treatment, genetic abnormalities, hemochromatosis, dysfunction of the pituitary gland, inflammatory disease, medication side effect, chronic kidney failure, liver cirrhosis, stress, alcoholism, obesity, Kallman's syndrome, idiopathic gonadotropin deficiency, Klinefelter's syndrome, pituitary hypothalamus injury due to tumours, osteoporosis, diabetes mellitus, chronic heart failure, chemotherapy, hemochromatosis, cirrhosis, renal failure, AIDS, sarcoidosis, Kallman's Syndrome, androgen receptor defects, 5-alpha reductase deficiency, myotonic dystrophy, cryptorchidism, mumps orchitis, aging, fertile eunuch syndrome, and pituitary disorders.
  • TDS testosterone deficiency syndrome
  • Patients have low circulating testosterone in combination with clinical symptoms such as fatigue, erectile dysfunction, and body composition changes. The cause may be primary (genetic anomaly, Klinefelter's syndrome) or secondary (defect in hypothalamus or pituitary), but often presents with the same symptomatology.
  • androgen deficiency of the aging male ADAM
  • Hypogonadal patients have alterations not only in sexual function and body composition, but also in cognition and metabolism. Regardless of etiology, hypogonadal patients who are both symptomatic and who have clinically significant alterations in laboratory values are candidates for treatment.
  • oral dosage forms of the invention can be used to raise an individual's plasma concentration of testosterone to a range of 300 ng/dL to 1050 ng/dL (including, 400 ng/dL to 950 ng/dL, 500 ng/dL to 950 ng/dL, and 600 ng/dL to 950 ng/dL) within five hours after administration under fasting or fed conditions.
  • Daily TU dosage amounts administered in oral dosage forms of the invention, employed for adult human TRT can be from 96 to 1,580 mg/day, which is the equivalent of about 60.75 to 1000 mg of testosterone/day.
  • Preferred daily TU dosage amounts administered in oral dosage forms of the invention, employed for adult human TRT are about 95 mg/60 kg body weight, about 192 mg/60 kg body weight, about 384 mg/60 kg body weight, about 768 mg/60 kg body weight, or about 1,152 mg/60 kg body weight.
  • an oral dosage form of the invention in with another therapeutic agent.
  • the other therapeutic agent can be separately administered, and administered by a different route.
  • the other therapeutic agent can be administered concurrently (e.g., simultaneously, essentially simultaneously or within the same treatment protocol) or sequentially, depending upon the nature of the disease, the condition of the patient, and the actual choice of compounds used.
  • kits can include a carrier, package, or container that is optionally compartmentalized to receive one or more doses of TU contained within a proliposomal powder dispersion or oral dosage forms of the invention.
  • the kits provided herein contain packaging materials. Examples of pharmaceutical packaging materials include strip packs, blister packs, bottles, tubes, bags, containers, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.
  • Testosterone Undecanoate uncoated, no-lipid control formulation TU1-044 To prepare TU1-044, 95 mg of testosterone undecanoate (TU), purchased from Pfizer Inc., Kalamazoo, Mich., weighed and manually filled into uncoated size 1 Vcaps® Plus capsules.
  • TU testosterone undecanoate
  • Testosterone Undecanoate enteric-coated, no-lipid control formulation TU1-076 To prepare TU1-076, 95 mg of testosterone undecanoate (TU), purchased from Pfizer Inc., Kalamazoo, Mich., weighed and manually filled into uncoated size 1 Vcaps® Plus capsules. The filled capsules were coated with methacrylic add copolymer NF, type C (Eudragit® L 30D-55). Vcaps® Plus capsules contain United States Pharmacopeia (USP)-grade Hydroxypropyl Methylcellulose and water.
  • UDP United States Pharmacopeia
  • Testosterone Undecanoate+DSPC+cholesterol (1.0:0.9:0.1) formulation TU1-040 To prepare TU1-040, TU (3.95 g) was dissolved in 19 mL EtOH, at 45-55° C., and mixed until a clear solution formed. Distearoylphosphatidylcholine (DSPC) (3.55 g) and cholesterol (0.395 g) were added to the drug solution, and the mixture continued to mix at 45-55° C., until a clear solution formed. Mixing and heating continued under vacuum until a dried mass formed. The dried mass was passed through a sieve No 60. The dried and screened powder was filled into uncoated Size “0” Vcaps® Plus capsules.
  • DSPC Distearoylphosphatidylcholine
  • cholesterol 0.395 g
  • Testosterone Undecanoate+DSPC+cholesterol+TPGS (1.0:0.9:0.1:0.05) formulation TU1-061c.
  • TU1-061c TU (1.9 g) was dissolved in 6.75 mL EtOH, at 45-55° C., and mixed until a clear solution formed.
  • DSPC 1.710 g
  • cholesterol 0.190 g
  • Vitamin E TPGS (95 mg) was dispensed into a separate bowl, and dissolved by mixing it in EtOH (approximately 0.3 mL), based on the ratio of (1.2 g of TPGS/4 mL of EtOH).
  • Microcrystalline cellulose (0.190 mg) (Avicel® PH 102) and 0.2 mL Ethanol were added to the TPGS solution, and mixed to form a slurry.
  • the TPGS/microcellulose slurry was added to the TU/DSPC/Chol solution, and the combination was mixed at 45-55° C. under a vacuum until the whole slurry became an agglomerate mass or several large masses, which were then broken down into smaller agglomerates and subjected to continued drying under a vacuum.
  • the dried mass was removed, and passed through a mill fitted with a Sieve No. 60 screen. Lumps of the dried mass that were hard to pass through the screen, were passed through a bigger screen before passing it through the smaller screen.
  • the milled dry mass was filled into Size “00” Vcaps® Plus capsules.
  • Testosterone Undecanoate+DSPC+cholesterol+TPGS (1.0:0.9:0.1:0.2) formulation TU1-061a.
  • TU1-061a TU (1.9 g) was dissolved in 6.75 ml EtOH, at 45-55° C., and mixed until a clear solution formed.
  • DSPC 1.710 g
  • cholesterol 0.190 g
  • Vitamin E TPGS (0.380 g) was dispensed into a separate bowl, and dissolved into in EtOH (1.26 mL), based on the ratio of (1.2 g of TPGS/4 mL of EtOH).
  • Microcrystalline cellulose (0.760 g) (Avicel® PH 102) and 0.8 mL EtOH were added to form a slurry.
  • the TPGS/microcellulose slurry was added to the TU/DSPC/Chol solution, and the combination was mixed at 45-55° C. under a vacuum until the slurry became an agglomerate mass, or several large masses, which were then broken down into smaller agglomerates and subjected to continued drying under vacuum.
  • the dried mass was removed, and passed through a mill fitted with a Sieve No. 60 screen. Lumps of the dried mass that were hard to pass through the screen, were passed through a bigger screen before passing it through the smaller screen.
  • the milled dry mass was filled into Size “00” Vcaps® Plus capsules.
  • Testosterone Undecanoate+DSPC (1.0:1.0) formulation TU1-027.
  • TU1-027 TU (11.875 g) was dissolved in 40 ml EtOH, at 45-55° C., and mixed until a clear solution formed.
  • DSPC (11.875 g) was added to the drug solution, and the mixture continued to mix at 45-55° C., until a clear solution formed. Mixing and heating continued under a vacuum until a dry mass was formed which, was then milled and screened through a sieve No 60 to obtained dry powder.
  • Microcrystalline cellulose (71.80 g) (Avicel® PH 102) and sodium starch glycolate (2.9 g) (Explotab®) were added to the dry powder, and the combined mixture blended for 20 min using a V blender.
  • the blended mixture was filled into Size “1” Vcaps® Plus capsules to a capsule fill weight of 202.5 mg/capsule, and the capsules were coated with Eudragit® L 30D-55.
  • Testosterone Undecanoate+DSPC (1.0:2.0) formulation TU1-028.
  • TU1-028 TU (11.875 g) was dissolved in 40 mL EtOH, at 45-55° C., and mixed until a clear solution formed.
  • DSPC 23.75 g was added to the drug solution, and the mixture continued to mix at 45-55° C., until a clear solution formed. Mixing and heating continued under a vacuum until a dry mass was formed which, was then milled and screened through a sieve No 60 to obtained dry powder.
  • Microcrystalline cellulose (63.38 g) (Avicel® PH 102) and sodium starchglycolate (3.01 g) (Explotab®) were added to the dry powder, and the combined mixture blended for 20 min using a V blender.
  • the blended mixture was filled into Size “1” Vcaps® Plus capsules to a capsule fill weight of 202.5 mg/capsule, and the capsules were coated with Eudragit® L 30D-55.
  • Testosterone Undecanoate+DSPC (1.0:4.0) formulation TU1-029.
  • TU1-029 TU (11.875 g) was dissolved in 40 mL EtOH, at 45-55° C., and mixed until a clear solution formed.
  • DSPC (47.5 g) was added to the drug solution, and the mixture continued to mix at 45-55° C., until a clear solution formed. Mixing and heating continued under a vacuum until a dry mass was formed which, was then milled and screened through a sieve No 60 to obtain a dry powder.
  • Microcrystalline cellulose (37.80 g) (Avicel® PH 102) and sodium starchglycolate (2.96 g) of (Explotab®) were added to the dry powder, and the combined mixture blended for 20 min using a V blender.
  • the blended mixture was filled into Size “1” Vcaps® Plus capsules to a capsule fill weight of 202.5 mg/capsule, and the capsules were coated with Eudragit® L 30D-55.
  • Testosterone Undecanoate+90 H (1.0:1.0) formulation TU1-030 To prepare TU1-030, TU (23.8 g) was dissolved in 40 mL EtOH, at 45-55° C., and mixed until a clear solution formed. Hydrogenated phosphatidylcholine 90 H (23.8 g) (purchased from Lipoid, LLC) was added to the drug solution, and the mixture continued to mix at 45-55° C., until a clear solution formed. Mixing and heating continued under vacuum until a dry mass was formed which was milled and screened through a sieve No 60 to obtain dry powder mass.
  • Microcrystalline cellulose (66.82 g) (Avicel® PH 102), and sodium starch glycolate (2.76 g) (Explotab®) were added to the dry powder, and the combined mixture blended for 20 min using a V blender.
  • the blended mixture was filled into Size “1” Vcaps® Plus capsules to a capsule fill weight of 202.5 mg/capsule, and the capsules were coated with Eudragit® L 30D-55.
  • Dissolution of proliposomal TU formulations in different media Dissolution studies were conducted for the control and proliposomal formulations described in Examples 1-9. With exception of the pure TU control formulation, dissolution data for each formulation was obtained by adding a capsule form of a formulation, containing 100 mg of TU to 750 mL of dissolution medium. These data are summarized in Table 1 and FIG. 1 .
  • the dissolution method involved two stages of testing, the Acid stage and the Buffer stage.
  • the Acid stage the dissolution was carried out in 750 mL of 0.1N HCl, and maintained at 37 ⁇ 0.5° C. for two hours. After two hours, a sample aliquot was withdrawn to be used in the buffer stage.
  • the capsules were removed from the dissolution apparatus after 2 h of dissolution in 0.1N HCl
  • 250 ml of 0.2M Tribasic sodium phosphate with containing 1% w/v SLS was added (SLS was not included in dissolution medium for TU1-044).
  • the final concentration of SLS in the combined media was 0.25% w/v.
  • the pH of the media was adjusted 6.80 with 2N HCl or 2N NaOH.
  • the dissolution data for control formulation TU1-044 did not contain SLS.
  • the dissolution study was run for four hours in buffer stage, and sample aliquots were withdrawn at regular time intervals. The samples were analyzed using a suitable analytical technique
  • HPLC analysis was carried out using a gradient method.
  • the mobile phase consisted of water and acetonitrile as follows: (90% water+10% acetonitrile) at 0 minutes; (4% water+96% acetonitrile) at 2 minutes; and (4% water+96% acetonitrile) at 15 minutes. Separation was achieved on a C18; 150 ⁇ 4.6 mm (5 ⁇ m) (Ace) column.
  • the mobile phase flow rate was set at 1.4 mL/min. while the column temperature was maintained at 40° C.
  • the total run time was 15 minutes with injection volume of 35 ⁇ l.
  • the testosterone was detected using a UV detector at absorbance maxima of 243 nm. The retention time of testosterone was found to be around 10 minutes. The method was able to resolve testosterone undecanoate and all other excipients.
  • TSX-002 (native T:Lipid), TSX-007 (native T:Lipid:TPGS (20% w/w of T)), and TSX-009 (TU:Lipid:TPGS (20% w/w of T)).
  • TSX-002, TSX-007, and TSX-009 formulations were orally administered to female beagle dogs under fasted or fed conditions. Fasted condition means animals were fasted overnight, dosing was performed the subsequent morning, and food was served two hours post-dosing. Animals were allowed access to food for another two hours, and monitored if they ate the food.
  • Fed condition means animals were fasted overnight, dosing was performed the subsequent morning, and food was served 15 min. post-dosing. Animals were allowed access to food for another two hours, and monitored if they ate the food. Blood samples were taken, at 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours. The administered dosage of TU was 7.5 mg/kg (TU/body weight). Plasma samples were analyzed on Day 1 and Day 7. Data based on TSX-002, TSX-007, and TSX-009 are reported in FIGS. 2A-2C , respectively.
  • TU 23.75 g
  • DSPC 21.3375 g
  • cholesterol 2.375
  • TPGS 4.75) g was dissolved in 60 ml EtOH separately.
  • the blended mixture was filled into Size “0” Vcaps® Plus capsules to a capsule fill weight of 303.75 mg/capsule, and the capsules were coated with Eudragit® L 30D-55.
  • Table 7 contains the amounts of ingredients per capsule for a TSX-009 formulation containing a 95 mg dose of TU (dose equivalent to 60 mg of T).
  • Testosterone Undecanoate+DSPC (1.0:1.0), admixed with microcrystalline cellulose at ratio of (Dispersion:Microcrystalline Cellulose) of ratio of 1:3.12, coated dosage form TSX-010 for female dog studies.
  • TU (11.875 g) was dissolved in 40 mL EtOH, at 45° C.-55, and mixed until a clear solution formed.
  • DSPC (11.875 g) was added to the drug solution, and the mixture continued to mix at 45-55° C., until a clear solution formed. Mixing and heating continued under a vacuum until a dry mass formed which was then milled and screened through a sieve No 60 to obtained dry powder mass.
  • Microcrystalline cellulose (37.80 g) (Avicel® PH 102) and 3.01 g sodium starch glycolate (Explotab®) were added to the dry powder, and the combined mixture blended for 20 min using a V blender.
  • the blended mixture was filled into Size “1” Vcaps® Plus capsules to a capsule fill weight of 202.5 mg/capsule, and the capsules were coated with Eudragit® L 30D-55.
  • Table 8 contains the amounts of ingredients per capsule for a TSX-010 formulation containing a 23.8 mg dose of TU (dose equivalent to 15 mg of T).
  • Testosterone Undecanoate+DSPC (1.0:2.0), admixed with microcrystalline cellulose at ratio of (Dispersion:Microcrystalline Cellulose) of ratio of 1:1.74, coated dosage form TSX-011 for female dog studies.
  • TU (11.875 g) was dissolved in 60 mL EtOH, at 45-55° C., and mixed until a clear solution formed.
  • DSPC 23.99 g was added to the drug solution, and the mixture continued to mix at 45-55° C., until a clear solution formed. Mixing and heating continued under a vacuum until a dry mass formed which was then milled and screened through a sieve No 60 to obtained dry powder mass.
  • Microcrystalline cellulose (63.38 g) (Avicel® PH 102) and sodium starch glycolate (Explotab®) were added to the dry powder, and the combined mixture blended for 20 min using a V blender.
  • the blended mixture was filled into Size “1” Vcaps® Plus capsules to a capsule fill weight of 202.5 mg/capsule, and the capsules were coated with Eudragit® L 30D-55.
  • Table 9 contains the amounts of ingredients per capsule for a TSX-011 formulation containing a 47.6 mg dose of TU (dose equivalent to 15 mg of T).
  • Testosterone Undecanoate+DSPC (1.0:4.0), admixed with microcrystalline cellulose at TU:MC ratio of 1:0.65, coated dosage form TSX-012.
  • TU (11.875 g) was dissolved in 120 mL EtOH, at 45-55° C., and mixed until a clear solution formed.
  • DSPC 147.5 g was added to the drug solution, and the mixture continued to mix at 45-55° C., until a clear solution formed. Mixing and heating continued under a vacuum until a dry mass formed which was then milled and screened through a sieve No 60 to obtained dry powder mass.
  • Microcrystalline cellulose (33.39 g) (Avicel® PH 102) and 2.96 g sodium starch glycolate (Explotab®) were added to the dry powder, and the combined mixture blended for 20 min using a V blender. The blended mixture was filled into Size “1” Vcaps® Plus capsules to a capsule fill weight of 202.5 mg/capsule, and the capsules were coated with Eudragit® L 30D-55. Table 10 contains the amounts of ingredients per capsule for a TSX-011 formulation containing a 23.8 mg dose of TU (dose equivalent to 15 mg of T).
  • TU, TSX-010, TSX-011, and TSX-012 were orally administered under either fasted or fed conditions.
  • the fasted condition means animals were fasted overnight, dosing was performed the subsequent morning, and food was served two hours post-dosing. Animals were allowed access to food for another two hours, and monitored if they ate the food.
  • the fed condition means animals were fasted overnight, dosing was performed the subsequent morning, and food was served 15 min. post-dosing.
  • TU blood samples were taken by venipuncture of the jugular vein at 0, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours in both fed and fasted conditions.
  • TU formulations like TSX-010, TSX-011, TSX-012 blood samples were taken by venipuncture of the jugular vein at 0, 4, 6, 8, 10, 12, 14, 16, 18 and 24 hours in fasted conditions and at 0, 1, 2, 4, 6, 8, 10, 12, 16 and 24 hours in fed conditions in femalebeagle dogs.
  • the administered dosages of TU were either 1.875, 3.75, or 7.5 mg/kg (TU/body weight).
  • Plasma testosterone concentration data was obtained at day 1 for formulations TSX-010, TSX-011, and TSX-012, and days 1 and 7, for unformulated TU. An animal was considered a non-responder if its plasma testosterone level did not exceed a 0.5 ng/mL quantification limit. Table 11 shows the fraction of animals that responded to the foregoing TU formulation treatments within a 24 hour time period.
  • Tables 12 and 13 report plasma T concentrations at each time point for formulation TSX-010, and these data are represented graphically in FIGS. 10A and 10B .
  • Tables 14 and 15 report plasma T concentrations at each time point for formulation TSX-011, and these data are represented graphically in FIGS. 11A and 11B .
  • Tables 16 and 17 report plasma T concentrations at each time point for formulation TSX-012, and these data are represented graphically in FIGS. 12A and 12B .
  • TSX-010 (TU:Lipid, 1:1), TSX-011 (TU:Lipid, 1:2), and TSX-012 (TU:Lipid, 1:4) in female Beagle dogs.
  • blood samples taken by jugular vein puncture at 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours, and the following pharmacokinetic (PK) parameters were analyzed for each formulation and unformulated testosterone and testosterone undecanoate.
  • Table 18 contains PK data for unformulated testosterone and testosterone undecanoate at days 1 and 7, under fasted and fed conditions.
  • Tables 19 and 20 contain PK data for the TSX-010, TSX-011, and TSX-012 formulations under fasted (Table 19) and fed (Table 20) conditions.
  • Unformulated TU showed better absorption under fed conditions as compared to fasted state, as evidenced by a two-fold increase in AUC and Cmax in the presence of food.
  • plasma profiles dropped significantly in comparison to animals which responded to the treatment with proliposomal formulations of TU.
  • TU formulations, TSX-010, -011, and -012 were tested in female beagle dogs to identify optimal TU to DSPC ratios and TU dosages, for further studies to performed using male dogs. Three dosage amounts were tested (1.87, 3.75, and 7.5 mg/Kg). Plasma levels were relatively high following administration of the 7.5 mg/Kg dose under fed and fasted conditions for all TSX-010, TSX-011, TSX-012.
  • TSX-011 which has a TU to DSPC ratio (w/w) of 1.0:2.0, was associated with higher TU absorption, followed by that of TSX-010 under fed conditions. There were no supra physiological levels of “T” in the presence of food for any of the TU formulations. However, TU formulated as TSX-012, did not absorb well under fed conditions, despite its higher TU to DSPC ratio of 1.0:4.0, but it was associated with relatively high AUC values under fasted conditions. TSX-011 with drug to lipid ratio of 1.0:2.0 had high responders with minimum variability and hence was selected to for further evaluation in male beagle dogs.
  • Testosterone Undecanoate+DSPC (1.0:2.0), admixed with microcrystalline cellulose at ratio of (Dispersion: Microcrystalline Cellulose) of ratio of 1:1.06, coated dosage form TSX-011 in male beaglgs.
  • TSX-011 was prepared as capsule containing TU Eq to 30 mg of T per capsules for studies in male beagle dogs.
  • TU 35.70 g
  • DSPC 71.40 g was added to the drug solution, and the mixture continued to mix at 45-55° C., until a clear solution formed.
  • Plasma testosterone concentrations after administration of TSX-011 (TU:Lipid, 1:2) to male Beagle dogs.
  • TSX-011 was orally administered under either fasted or fed conditions in male beagle dogs.
  • the fasted condition means animals were fasted overnight, dosing was performed the subsequent morning, and food was served two hours post-dosing. Animals were allowed access to food for another two hours, and monitored if they ate the food.
  • the fed condition means animals were fasted overnight, dosing was performed the subsequent morning, and food was served 15 min. post-dosing.
  • a study was also performed with high fat meals containing 21% fat based on dry basis and 41% fat based on calories.
  • Plasma testosterone concentration data, for TSX-011 under fasted/fed conditions are compiled in Table 22, 23 and the same data is graphically represented in FIGS. 13A, 13B .
  • Increasing the dose from QD to BID enhanced the plasma profile of TSX-011 both in fed and fasted conditions.
  • presence of high fat did not show any supra physiological levels of T with TSX-011.
  • the food effect was minimum as the difference in the AUC of QD/Fed and QD/Fed/High fat was not significant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
US16/068,190 2016-01-08 2017-01-09 Proliposomal testosterone undecanoate formulations Abandoned US20190248830A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/068,190 US20190248830A1 (en) 2016-01-08 2017-01-09 Proliposomal testosterone undecanoate formulations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662276452P 2016-01-08 2016-01-08
US201662394576P 2016-09-14 2016-09-14
PCT/US2017/012739 WO2017120592A1 (en) 2016-01-08 2017-01-09 Proliposomal testosterone undecanoate formulations
US16/068,190 US20190248830A1 (en) 2016-01-08 2017-01-09 Proliposomal testosterone undecanoate formulations

Publications (1)

Publication Number Publication Date
US20190248830A1 true US20190248830A1 (en) 2019-08-15

Family

ID=59274044

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/068,190 Abandoned US20190248830A1 (en) 2016-01-08 2017-01-09 Proliposomal testosterone undecanoate formulations

Country Status (6)

Country Link
US (1) US20190248830A1 (https=)
EP (1) EP3399965A4 (https=)
JP (1) JP2019501199A (https=)
KR (1) KR20180101452A (https=)
CN (1) CN108601736A (https=)
WO (1) WO2017120592A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200022991A1 (en) * 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
US11179403B2 (en) 2010-04-12 2021-11-23 Clarus Therapeutics, Inc. Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US11179402B2 (en) 2005-04-15 2021-11-23 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US12605391B2 (en) 2019-04-12 2026-04-21 Tolmar, Inc. Methods of treating testosterone deficiency

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3709979T1 (sl) 2017-11-17 2025-03-31 Evonik Operations Gmbh Postopek za pripravo obložene kapsule s trdo ovojnico
US20200197412A1 (en) * 2018-12-20 2020-06-25 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
US20220265679A1 (en) * 2019-08-09 2022-08-25 Tesorx Pharma, Llc Proliposomal testosterone undecanoate formulations
GB202307501D0 (en) * 2023-05-19 2023-07-05 Lawley Pharmaceuticals Pty Ltd Process for preparing dispensable testosterone cream

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140112986A1 (en) * 2012-05-09 2014-04-24 Tesorx Pharma, Llc Proliposomal testosterone formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
EP2034961A1 (de) * 2006-06-30 2009-03-18 Gertrud Langhoff Solubilisatformulierungen
EP2146692A1 (en) * 2007-03-19 2010-01-27 Fresenius Kabi Oncology Limited Proliposomal and liposomal compositions
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
US20140309202A1 (en) * 2010-11-30 2014-10-16 Lipocine Inc. High-strength testosterone undecanoate compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140112986A1 (en) * 2012-05-09 2014-04-24 Tesorx Pharma, Llc Proliposomal testosterone formulations
US8957053B2 (en) * 2012-05-09 2015-02-17 Tesorx Pharma, Llc Proliposomal testosterone formulations
US9445995B2 (en) * 2012-05-09 2016-09-20 Western University Of Health Sciences Proliposomal testosterone formulations
US9623033B2 (en) * 2012-05-09 2017-04-18 Western University Of Health Sciences Proliposomal testosterone formulations
US9844557B2 (en) * 2012-05-09 2017-12-19 Western University Of Health Sciences Proliposomal testosterone formulations

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179402B2 (en) 2005-04-15 2021-11-23 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US11331325B2 (en) 2005-04-15 2022-05-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US11179403B2 (en) 2010-04-12 2021-11-23 Clarus Therapeutics, Inc. Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US11426416B2 (en) 2010-04-12 2022-08-30 Clarus Therapeutics, Inc. Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US20200022991A1 (en) * 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
US12605391B2 (en) 2019-04-12 2026-04-21 Tolmar, Inc. Methods of treating testosterone deficiency

Also Published As

Publication number Publication date
CN108601736A (zh) 2018-09-28
EP3399965A4 (en) 2019-08-21
JP2019501199A (ja) 2019-01-17
WO2017120592A1 (en) 2017-07-13
EP3399965A1 (en) 2018-11-14
KR20180101452A (ko) 2018-09-12

Similar Documents

Publication Publication Date Title
US20190248830A1 (en) Proliposomal testosterone undecanoate formulations
EP3110408B1 (en) Controlled release enteric soft capsules of fumarate esters
AU2017272249B2 (en) Proliposomal testosterone formulations
US20050249799A1 (en) Polymeric drug delivery system for hydrophobic drugs
US12133917B2 (en) Pediatric dosage forms, methods of making and using
EP2964197B1 (en) Solid compositions comprising a glucokinase activator and methods of making and using the same
JP6356215B2 (ja) エベロリムスを含む医薬組成物
CN103874484A (zh) 包含40-o-(2-羟基)乙基-雷帕霉素的药物组合物
US20100015225A1 (en) Solid dispersion of a neurokinin antagonist
KR102300335B1 (ko) 아프레피탄트의 경구용 조성물
JP2019163327A (ja) 三種混合製剤
KR100980752B1 (ko) 담체 표면 상에 흡착된 페노피브레이트를 포함하는 과립 및 이를 포함하는 약학 조성물
TWI867026B (zh) 前體脂質體十一酸睪固酮調配物
TW201811336A (zh) 前體脂質體十一酸睪固酮調配物
HK1259799A1 (en) Proliposomal testosterone undecanoate formulations
HK1151466B (en) Oral pharamaceutical composition of glycyrrhizin or its salts and the preparation method thereof
HK1151466A1 (en) Oral pharamaceutical composition of glycyrrhizin or its salts and the preparation method thereof
HK1211499B (zh) 前体脂质体睾酮制剂

Legal Events

Date Code Title Description
AS Assignment

Owner name: WESTERN UNIVERSITY OF HEALTH SCIENCES, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BETAGERI, GURU V.;REEL/FRAME:046356/0337

Effective date: 20180706

Owner name: TESORX PHARMA, LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:THIRUCOTE, RAMACHANDRAN;KADAJJI, VEERAN GOWDA;VENKATESAN, NATARAJAN;SIGNING DATES FROM 20180706 TO 20180709;REEL/FRAME:046356/0441

AS Assignment

Owner name: TESORX PHARMA, LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:THIRUCOTE, RAMACHANDRAN;KADAJJI, VEERAN GOWDA;VENKATESAN, NATARAJAN;SIGNING DATES FROM 20180706 TO 20180709;REEL/FRAME:047678/0225

Owner name: WESTERN UNIVERSITY OF HEALTH SCIENCES, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BETAGERI, GURU V.;REEL/FRAME:047678/0250

Effective date: 20180706

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION